Jane Wasman,
Vice Chair

jwasman@outlook.com
(917)386-7934

Ms. Wasman is the Chair of the Board of Directors of Sellas Life Sciences (Nasdaq: SLS), an oncology-focused biotech company, as well as Chair of its Nominations & Governance Committee and member of its Audit, Compensation and Finance Committees. She also is on the Board of Rigel Pharmaceuticals, an immune/rare disease-focused public biotech company (Nasdaq: RIGL), and is a member of its Nominations & Governance/Compliance and Science Committees. She has served since 2007 on the board of NY BIO, including its Executive Committee and Public Policy Committee (Chair). In 2020, she became Vice Chair of the Board of the Mirimus Foundation.

Ms. Wasman is Founder and President of JWasman Advisors, a consulting firm focused on strategic, operational and corporate governance matters for biopharma and life sciences organizations ranging from startups to publicly traded companies. Ms. Wasman previously served as President, International, General Counsel and Chief, Strategic Development at Acorda Therapeutics (Nasdaq: ACOR), where she led long-range planning and development in addition to international expansion. She played a central role in Acorda’s IPO and transition from a private, development stage entity to a public, commercial company, including as a lead member of the teams for commercialization, licensing/M&A strategy and implementation, investor relations, product pipeline development and government affairs activities. She also helped build Acorda’s corporate governance/board infrastructure, and worked closely with the board of directors on strategic, operational and governance matters.

Ms. Wasman built and managed Acorda’s legal, compliance, IP and quality functions. Her department was recognized as one of four “Best Legal Departments” nationally by Corporate Counsel. Additionally, she led the legal process for two key

acquisitions - the $525M acquisition of Civitas Therapeutics and the first-ever acquisition of a dual stock exchange-listed Finnish company, Biotie Therapies, in a $400M transaction.

Ms. Wasman graduated magna cum laude from Princeton University, and earned her J.D. from Harvard Law School. She currently resides in New York City.